Long-Term Cost-Effectiveness Analyses of Empagliflozin versus Oral Semaglutide, in Addition to Metformin, For the Treatment of Type 2 Diabetes in the UK
mediaposted on 2020-07-21, 08:58 authored by Mafalda Ramos, Michael H. Cummings, Anastasia Ustyugova, Syed I. Raza, Shamika U. de Silva, Mark Lamotte
The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2020.